Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

First Posted Date
2024-03-21
Last Posted Date
2024-03-21
Lead Sponsor
Jinling Hospital, China
Target Recruit Count
80
Registration Number
NCT06324266
Locations
🇨🇳

Jinling Hospital, Nanjing, Jiangsu, China

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

First Posted Date
2024-03-20
Last Posted Date
2024-03-25
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
30
Registration Number
NCT06321289
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

🇨🇳

School of medicine, Tsinghua University & Changping Laboratory, Beijing, China

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

First Posted Date
2024-03-19
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
171
Registration Number
NCT06317662

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

First Posted Date
2024-03-19
Last Posted Date
2024-12-13
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
28
Registration Number
NCT06318897
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

First Posted Date
2024-03-15
Last Posted Date
2024-03-15
Lead Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Target Recruit Count
300
Registration Number
NCT06313996

FT819 in Moderate to Severe Active Systemic Lupus Erythematosus

First Posted Date
2024-03-13
Last Posted Date
2024-08-07
Lead Sponsor
Fate Therapeutics
Target Recruit Count
64
Registration Number
NCT06308978
Locations
🇺🇸

University of Minnesota Medical School, Minneapolis, Minnesota, United States

🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

First Posted Date
2024-03-12
Last Posted Date
2024-10-26
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
27
Registration Number
NCT06305299
Locations
🇺🇸

Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

First Posted Date
2024-03-08
Last Posted Date
2024-12-03
Lead Sponsor
Guangzhou FineImmune Biotechnology Co., LTD.
Target Recruit Count
23
Registration Number
NCT06302062
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Gaungdong, China

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

First Posted Date
2024-03-04
Last Posted Date
2024-08-16
Lead Sponsor
University of Chicago
Target Recruit Count
85
Registration Number
NCT06291064

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

First Posted Date
2024-02-28
Last Posted Date
2024-10-11
Lead Sponsor
The Lymphoma Academic Research Organisation
Target Recruit Count
790
Registration Number
NCT06284122
Locations
🇫🇷

HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France

🇫🇷

GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France

🇫🇷

CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France

and more 46 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy